Atlas Trials

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

Clinical trial NCT05213143 · TERMINATED

Trial details

NCT number
NCT05213143
Sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Status
TERMINATED
Phase
Phase 4
Study type
INTERVENTIONAL
Schizophrenia
Start date
2021-12-30
Primary completion
2022-11-18
Enrollment
13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.